Zobrazeno 1 - 10
of 172
pro vyhledávání: '"R. Strohl"'
Autor:
Hailong Guo, Sha Ha, Jason W. Botten, Kai Xu, Ningyan Zhang, Zhiqiang An, William R. Strohl, John W. Shiver, Tong-Ming Fu
Publikováno v:
Viruses, Vol 16, Iss 5, p 697 (2024)
Since the SARS-CoV-2 Omicron virus has gained dominance worldwide, its continual evolution with unpredictable mutations and patterns has revoked all authorized immunotherapeutics. Rapid viral evolution has also necessitated several rounds of vaccine
Externí odkaz:
https://doaj.org/article/9f434c9a18824f788d9203181f6e2477
Autor:
Hailong Guo, Bomsoo Cho, Paul R. Hinton, Sijia He, Yongjun Yu, Ashwin Kumar Ramesh, Jwala Priyadarsini Sivaccumar, Zhiqiang Ku, Kristen Campo, Sarah Holland, Sameer Sachdeva, Christopher Mensch, Mohamed Dawod, Annalis Whitaker, Philip Eisenhauer, Allison Falcone, Rebekah Honce, Jason W. Botten, Stephen F. Carroll, Bruce A. Keyt, Andrew W. Womack, William R. Strohl, Kai Xu, Ningyan Zhang, Zhiqiang An, Sha Ha, John W. Shiver, Tong-Ming Fu
Publikováno v:
Emerging Microbes and Infections, Vol 12, Iss 2 (2023)
The capacity of SARS-CoV-2 to evolve poses challenges to conventional prevention and treatment options such as vaccination and monoclonal antibodies, as they rely on viral receptor binding domain (RBD) sequences from previous strains. Additionally, a
Externí odkaz:
https://doaj.org/article/b32daa709614466280c100d037969216
Autor:
William R. Strohl
Publikováno v:
Protein & Cell, Vol 9, Iss 1, Pp 86-120 (2017)
ABSTRACT As of May 1, 2017, 74 antibody-based molecules have been approved by a regulatory authority in a major market. Additionally, there are 70 and 575 antibody-based molecules in phase III and phase I/II clinical trials, respectively. These total
Externí odkaz:
https://doaj.org/article/70249a08e9fb485ca8526adc0e435df3
Autor:
Zhiqiang An, Ningyan Zhang, Robert E. Jordan, William R. Strohl, Michael Rycyzyn, Songlin Zhang, Anneliese Gonzalez, Yun Shi, Pooja M. Dhupkar, Hui Deng, Randall J. Brezski, Xuejun Fan
Primary and acquired resistance to anticancer antibody immunotherapies presents significant clinical challenges. Here, we demonstrate that proteolytic inactivation of cancer-targeting antibodies is an unappreciated contributor to cancer immune evasio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02ad692cacda30dfffc07c45087dd8e9
https://doi.org/10.1158/1535-7163.c.6536878.v1
https://doi.org/10.1158/1535-7163.c.6536878.v1
Autor:
Zhiqiang An, Ningyan Zhang, Robert E. Jordan, William R. Strohl, Michael Rycyzyn, Songlin Zhang, Anneliese Gonzalez, Yun Shi, Pooja M. Dhupkar, Hui Deng, Randall J. Brezski, Xuejun Fan
Figure S1: IdeS expression in BT474 breast cancer cells Figure S2: Detection of MMPs in cancer cell lysates and culture supernatant Figure S3: scIgG-T was not in the SKBR-3 cell culture medium Figure S4: Detection of immune cells infiltration in mice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85565468aba8994762d92893b5ffd8e3
https://doi.org/10.1158/1535-7163.22501711.v1
https://doi.org/10.1158/1535-7163.22501711.v1
Autor:
William R. Strohl, Michael Naso
Publikováno v:
Antibodies, Vol 8, Iss 3, p 41 (2019)
The concepts for T-cell redirecting bispecific antibodies (TRBAs) and chimeric antigen receptor (CAR)-T cells are both at least 30 years old but both platforms are just now coming into age. Two TRBAs and two CAR-T cell products have been approved by
Externí odkaz:
https://doaj.org/article/24215a44281d460cbabbd80abe9e86a8
Autor:
Peter T. Buckley, Rita Chan, Jeffrey Fernandez, Jinquan Luo, Keenan A. Lacey, Ashley L. DuMont, Aidan O’Malley, Randall J. Brezski, Songmao Zheng, Thomas Malia, Brian Whitaker, Adam Zwolak, Angela Payne, Desmond Clark, Martin Sigg, Eilyn R. Lacy, Anna Kornilova, Debra Kwok, Steve McCarthy, Bingyuan Wu, Brian Morrow, Jennifer Nemeth-Seay, Ted Petley, Sam Wu, William R. Strohl, Anthony Simon Lynch, Victor J. Torres
Publikováno v:
Cell Host & Microbe. 31:751-765.e11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4756f7a8083a9d7782669668c12b6439
https://doi.org/10.1016/j.chom.2023.04.004
https://doi.org/10.1016/j.chom.2023.04.004
Autor:
William R. Strohl, Zhiqiang Ku, Zhiqiang An, Stephen F. Carroll, Bruce A. Keyt, Lila M. Strohl
Publikováno v:
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 36(3)
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people infected and nearly six million dead worldwide, making it the most significant pandemic since the 1918 influenza pandemic. The severity and significance of SARS-C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::580c5abe08041685b53040417c215d3a
https://pubmed.ncbi.nlm.nih.gov/35476216
https://pubmed.ncbi.nlm.nih.gov/35476216
Autor:
Thomas Valerius, Paul W. H. I. Parren, Janine Schuurman, Joost J. Neijssen, William R. Strohl, Kristen M. Chevalier, Luus Wiegman, Cardoso Rosa Maria Fernandes, Mark L. Chiu, Sheri Moores, G. Mark Anderson
Publikováno v:
The Journal of Biological Chemistry
Journal of Biological Chemistry, 296. ELSEVIER
Journal of Biological Chemistry, 296. ELSEVIER
A bispecific antibody (BsAb) targeting the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) pathways represents a novel approach to overcome resistance to targeted therapies in patients with nonsmall cell lun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca933b2c86ba6635402921bd327c1a34
https://hdl.handle.net/1887/3256851
https://hdl.handle.net/1887/3256851
Frontiers and Opportunities: Highlights of the 2nd Annual Conference of the Chinese Antibody Society
Autor:
Mi Deng, Mitchell Ho, William R Strohl, Hongyu Zhang, Peng Lin, Shouye Wang, Junjian Liu, Cheng Liu
Publikováno v:
Antibody Therapeutics. 1:27-36
The Chinese Antibody Society (CAS) convened the second annual conference in Cambridge, MA, USA on 29 April 2018. More than 600 members from around the world attended the meeting. Invited speakers discussed the latest advancements in therapeutic antib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da1c14f9315f5cec0980196b9225868b
https://doi.org/10.1093/abt/tby009
https://doi.org/10.1093/abt/tby009